DHR Stock Recent News

Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.

Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Tuesday, May 14, 2024 at 10:40 a.m.

One of the best ways to grab a dividend payer set to surge is a strategy you never hear about anymore: Pick up shares of a conglomerate.

Danaher stock (NYSE: DHR), a conglomerate with products in life sciences, biotechnology, and diagnostics fields, recently posted its Q1 results that exceeded the street expectations. The company reported revenue of $5.8 billion and adjusted earnings of $1.92 per share, compared to the consensus estimates of $5.3 billion and $1.60, respectively.

While Danaher (DHR) surpasses first-quarter earnings and revenue estimates, its performance is hurt by a decrease in core sales in the Biotechnology segment.

PulteGroup received an added data boost, Danaher's markets are looking up, and JetBlue collapses, despite a not-as-bad-as-feared loss.

Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The medical company reported first-quarter adjusted earnings of $1.92 a share, beating Wall Street's call for $1.72.

Danaher (DHR) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.72 per share. This compares to earnings of $2.36 per share a year ago.